A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma.

February 4, 2013, from MedWorm: Brain Tumor

CONCLUSIONS: The antitumor activity of this combination at the phase II dose tested was limited. Pharmacokinetic data indicated that exposure to lapatinib was subtherapeutic in the phase II evaluation. Evaluation of intratumoral drug delivery and activity may be essential for hypothesis-testing trials with targeted agents in malignant glioma. Clin Cancer Res; 19(4); 1-9. ©2012 AACR. PMID: 23363814 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research) View Source